Literature DB >> 16478852

Systemic inflammatory reaction after thoracoscopic talc poudrage.

Marios E Froudarakis1, Maria Klimathianaki, Mihalis Pougounias.   

Abstract

BACKGROUND: Recent studies have reported fever as a side effect of talc poudrage during thoracoscopic pleurodesis. However, thoracoscopy itself is likely to induce systemic inflammatory reaction, as it is an interventional procedure. The aim of the study was to investigate whether systemic inflammatory response is due to talc poudrage or to thoracoscopy.
METHODS: We prospectively studied two groups of patients. The first group (18 patients) underwent thoracoscopic talc poudrage, and the second group (17 patients) underwent only diagnostic thoracoscopy. We measured body temperature, as well as WBC count and C-reactive protein (CRP) levels before the procedure (baseline), and at 24 and 48 h after the procedure. No antiinflammatory medication was permitted to be used before, during, or after the procedure. All patients had a 3-month follow-up.
RESULTS: The baseline patient characteristics were similar in both groups. Temperature increased significantly in the thoracoscopic talc poudrage group (overall comparison, p = 0.005) especially at 9, 12, and 24 h after the procedure. Overall, the WBC count (p = 0.004), percentage of neutrophils (p = 0.03), and CRP levels (p < 0.0001) were significantly increased in the group of patients who underwent thoracoscopic talc poudrage. On the contrary, lymphocytes were significantly decreased (overall comparison, p = 0.01) in the thoracoscopic talc poudrage group during the same period. Mild side effects, such as pain during and after thoracoscopy and subcutaneous emphysema, were noted. No severe complication, such as infection or acute respiratory failure, was noted in either group during the hospitalization or during the follow-up period.
CONCLUSION: According to our results, fever and systemic inflammatory reaction is due to talc poudrage and not to thoracoscopy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16478852     DOI: 10.1378/chest.129.2.356

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Application of talcum powder, trichloroacetic acid and silver nitrate in female rats for non-surgical sterilization: evaluation of the apoptotic pathway mRNA and miRNA genes.

Authors:  Onder Yumrutas; Murat Kara; Remzi Atilgan; Salih Burcin Kavak; Ibrahim Bozgeyik; Ekrem Sapmaz
Journal:  Int J Exp Pathol       Date:  2015-04-17       Impact factor: 1.925

Review 2.  Management of malignant pleural effusion.

Authors:  Hongbin Chen; Julie Brahmer
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

3.  Clinical factors affecting the survival of patients diagnosed with non-small cell lung cancer and metastatic malignant pleural effusion, treated with hyperthermic intrathoracic chemotherapy or chemical talc pleurodesis: a monocentric, prospective, randomized trial.

Authors:  Athanasios Kleontas; Antonia Sioga; Niki Pandria; Nikolaos Barbetakis; Achilleas Lazopoulos; Ioannis Katsikas; Christos Asteriou; Dimitrios Paliouras; Efstathios Kamperis; Dimitrios Ikonomou; Theodora Papamitsou; Dimitrios Filippou; Chariklia Destouni; Louiza Ikonomou; Konstantinos Zarogoulidis; Kostas Papagiannopoulos
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

4.  Chemical Pleurodesis Using Doxycycline and Viscum album Extract.

Authors:  Kyung Sub Song; DongYoon Keum; Jae Bum Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2017-08-05

5.  Viscum pleurodesis is as effective as talc pleurodesis and tends to have less adverse effect.

Authors:  YongJin Chang; DeogGon Cho; KyuDo Cho; MinSeop Cho
Journal:  Support Care Cancer       Date:  2020-03-12       Impact factor: 3.603

Review 6.  Complications of thoracoscopic talc insufflation for the treatment of malignant pleural effusions: a meta-analysis.

Authors:  Wen Zhang; Yun-Long Zhao; Shao-Jun Li; Ying-Nan Zhao; Nan-Nan Guo; Bo Liu
Journal:  J Cardiothorac Surg       Date:  2021-05-04       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.